The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers.
$62.36-1.81%
报价 2026-11-06
市值
$11.86B
EV
$13.32B
PE (TTM)
19.1x
预期 PE (FY2027)
13.3x
52 周区间距高点 -26.0%
$53.27$84.32
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-10 | 1.1x | 4.61 → 5.08（1.1x） | 12.3 |
| FY+32029-10 | 1.2x | 4.61 → 5.53（1.2x） | 11.3 |
毛利率 64% · TTM 收入 $4237M · 基数 EPS 4.61（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| COOThe Cooper Companies, Inc. | $11.86B | -1.8% | +4.0% | 62.4% | 19.1x | 14.6x | 16.1x | |
| NBIXNeurocrine Biosciences, Inc. | $16.66B | +3.0% | +39.8% | 97.6% | 23.6x | 17.3x | 16.0x | 高增长 |
| SOLVSolventum Corporation | $15.38B | +3.7% | -0.7% | 53.5% | 7.3x | 5.5x | – | |
| ICLRICON Public Limited Company | $15.34B | +1.5% | +1.6% | 19.6% | 34.7x | 13.4x | 12.2x | |
| TEMTempus AI, Inc. | $13.49B | +8.0% | +26.3% | 72.3% | – | – | – | |
| SNNSmith & Nephew plc | $13.41B | -2.7% | – | 68% | 22.0x | 10.3x | – | |
| SMMTSummit Therapeutics Inc. | $13.03B | +15.1% | -82.9% | 0% | – | – | – | |
| FMSFresenius Medical Care AG & Co. KGaA | $12.45B | -1.1% | – | 25.6% | 11.0x | 6.1x | – | Cheap |
| UHSUniversal Health Services, Inc. | $10.1B | -1.6% | +7.1% | 9.6% | 8.1x | 5.8x | 9.1x | Cheap |
| 同行中位数 | – | – | +4.4% | 39.5% | 16.5x | 8.2x | 12.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-07-31 Q3 2026 | 2026-04-30 Q2 2026 | 2026-01-31 Q1 2026 | 2025-10-31 Q4 2025 | 2025-07-31 Q3 2025 | 2025-04-30 Q2 2025 | 2025-01-31 Q1 2025 | 2024-10-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $1.08B | $1.02B | $1.07B | $1.06B | $1B | $964.7M | $1.02B |
| Gross Margin | 62.4% | 68% | 67.9% | 56.4% | 65.3% | 67.8% | 68.4% | 66.5% |
| Operating Margin | 20.9% | -2.9% | 20.8% | 13.2% | 16.6% | 18.4% | 18.9% | 19.5% |
| Net Income | $432.8M | $-77.9M | $130.8M | $84.6M | $98.3M | $87.7M | $104.3M | $117.5M |
| Diluted EPS | 2.24 | -0.4 | 0.66 | 0.43 | 0.49 | 0.44 | 0.52 | 0.58 |
| Operating Cash Flow | $341.7M | $182.8M | $260.9M | $247.9M | $261.4M | $96.2M | $190.6M | $268.1M |